genes prME and NS1 were examined. Cells transfected with rSFV-prME RNA showed correct processing of the precursor prME and the release into the medium of M and E proteins in particulate form, whilst rSFV-NS1-transfected cells secreted glycosylated, heat-labile NS1 dimers. Mice immunized with rSFV particles produced antibodies against prME and NS1 that were mainly of the IgG2a subtype, indicating that a T-helper 1 immune response was induced. Immunization with prME-or NS1-encoding particles induced T-cell proliferation. Mice vaccinated intraperitoneally (i.p.) with rSFVprME and/or rSFV-NS1 were significantly protected from lethal i.p. challenge by two strains of LIV, the virulent LI/31 strain, from which the commercial LIV vaccine is derived, and the less-virulent LI/I antibody-escape variant. Intranasal (i.n.) vaccination was protective for rSFV-prME only against LI/31 challenge and not against challenge with LI/I. Immunization with rSFV-NS1 was protective against i.p. and i.n. challenge with both virus strains when given i.p., but was not protective when given i.n. For unvaccinated mice infected with LIV, all animals showing clinical signs had severe degenerative and inflammatory lesions in the central nervous system. None of the rSFV-vaccinated mice that survived challenge showed central nervous system pathology, with the exception of mild leptomeningitis in a minority of LI/31-infected mice. This suggests that protection following immunization with rSFV must occur at early stages of LIV infection.
Introduction
The use of recombinant viruses is one of the central approaches for the development of vaccines against infectious disease. The aim is to combine the efficacy of live or attenuated vaccines with the safety of subunit vaccines. Especially in the case of virus vaccines using viral vectors, one could conceivably achieve a situation where vaccination mimics an infection by the cognate agent. However, safety problems and strong immune responses against the vectors themselves are drawbacks of some viral vectors. Therefore, viral vector Author for correspondence : Peter Liljestro$ m (at the Karolinska Institutet). Fax j46 8 310 848. e-mail Peter.Liljestrom!mtc.ki.se systems have been developed that do not lead to productive replication in the host (Moss, 1996 ; Paoletti, 1996) and more recently, nucleic acid vaccination has attracted much attention (Koprowski & Weiner, 1998) .
We are interested in using the Semliki Forest virus (SFV) expression system for vaccination (Berglund et al., 1993 ; Liljestro$ m & Garoff, 1991) . SFV particles that carry a recombinant RNA molecule (rSFV) undergo only one round of RNA replication in the infected cell. The genes for the SFV structural proteins are replaced by the antigen-encoding gene and, as a result, no progeny virus can be produced. Moreover, the cell is killed by the replicating vector within a few days (Berglund et al., 1998 ; Glasgow et al., 1998) . We have shown previously that vaccination of mice with antigen-encoding SFV vectors results in induction of strong humoral and cellular immune responses (Berglund et al., 1998 (Berglund et al., , 1999 Zhou et al., 1994 Zhou et al., , 1995 .
In this study we have used rSFV expressing antigens of louping ill virus (LIV) as a vaccine model. LIV is a member of the genus Flavivirus within the family Flaviviridae. This genus includes some of the most important human pathogens, such as yellow fever virus, Japanese encephalitis virus, dengue virus and the tick-borne encephalitis virus complex, of which LIV is part (Monath & Heinz, 1996 ; Rice, 1996) . Despite the availability of commercial vaccines for some of these viruses, there remains a need for inexpensive, safe and more effective vaccines (Kanesa-thasan et al., 1997) . The recent construction of full-length, infectious cDNA clones of several flaviviruses (Lai et al., 1991 ; Mandl et al., 1997 ; Sumiyoshi et al., 1992) will allow detailed analysis of flavivirus replication, characterization of virulence determinants and new approaches to vaccination.
LIV is prevalent in tick-infested upland pastures in Britain and Ireland and is known primarily as a cause of disease in sheep (McGuire et al., 1998) but has also been shown to infect and cause disease in deer, cattle, goats and grouse (Monath & Heinz, 1996) . Moreover, there have been at least 37 documented cases of LIV infection in man, which were probably transmitted by aerosol during laboratory experimentation or diagnosis rather than by tick bites (Collins, 1988 ; Davidson et al., 1991) .
Flavivirus proteins are encoded by a single, long open reading frame present in the positive-strand RNA genome (Fig.  1) . Cleavage of the polyprotein by host-cell signal peptidase and the virus-encoded protease generates the structural (C, prM, E) and nonstructural (NS1-NS5) proteins (Rice, 1996) . We have chosen the envelope proteins (prM and E) and NS1 for our study because these antigens have previously been reported to elicit good immune responses Jacobs et al., 1992 ; Konishi et al., 1992 ; Lin et al., 1998 ; Pugachev et al., 1995 b ; Schlesinger et al., 1986 ; Schmaljohn et al., 1997) . The prM protein is the precursor of the virionassociated M protein and is found in intracellular immature virions. prM forms heterodimers with E in the endoplasmic reticulum (ER), thereby allowing proper folding of E and exit from the ER (Allison et al., 1995 b ; Guirakhoo et al., 1991 ; Schalich et al., 1996) . The E protein is required for virus entry and is the major target for neutralizing antibodies (Rey et al., 1995) .
The function of the nonstructural glycoprotein NS1 is not clear but it is believed to be involved in viral RNA synthesis (Lindenbach & Rice, 1997 ; Mackenzie et al., 1996 ; Muylaert et al., 1997) . NS1 is found in three forms, intracellular (within the lumen of the ER), plasma membrane-associated and extracellular (Chambers et al., 1990 ; Fan & Mason, 1990 ; Mackenzie et al., 1996) . A potential advantage of including NS1 in a flavivirus vaccine would be to elicit protective immunity without problems associated with antibody-dependent enhancement (Halstead, 1988) , although, in contrast to dengue virus, antibody-dependent enhancement is not believed to occur with tick-borne encephalitis virus infection (Kreil & Eibl, 1997) . Secondly, immune responses to NS1 would elicit protection against envelope protein virus variants, which may escape neutralization. Our results in this study show that vaccination of mice with suicidal rSFV vectors expressing prME and\or NS1 elicit strong immune responses that provide protective immunity against lethal challenge with different strains of LIV, one of which is an antibody-escape variant.
Methods
Cells and antibodies. BHK-21 cells were maintained and transfected as described previously (Liljestro$ m & Garoff, 1991) . For immunoprecipitation, immunofluorescence and immunocytochemistry, anti-E MAb 4.2, anti-NS1 MAb 7.3 and a rabbit hyperimmune antiserum (which reacts with the structural proteins and NS1 of LIV) were used and have been described elsewhere (Gao et al., 1994) .
LIV stocks. The origin and properties of the prototype LI\31 strain of LIV and the antibody-escape variant LI\I have been described previously (Gao et al., 1994 ; McGuire et al., 1998) . LI\31 is fully virulent in mice, whereas LI\I is a naturally occurring, antibody-escape variant isolated from an infected sheep and is partially attenuated. The relevant escape mutation has been mapped to an epitope containing amino acid residue 308 in the E protein, which is responsible for neutralization by antibodies (Jiang et al., 1993) . Virus stocks were prepared by homogenization of brains from moribund neonatal mice infected intracerebrally with LIV (Gao et al., 1994) and were titrated by lethal dose assay following intraperitoneal (i.p.) or intranasal (i.n.) infection of adult mice.
Construction of plasmids.
Standard DNA techniques were used in the construction of recombinant plasmids encoding genes derived from the LI\369 strain of LIV (Shiu et al., 1992) . The genes encoding prME genes were isolated from pSC11-LIprME (Shiu et al., 1992) as a BglII fragment and ligated into the BamHI site of pSFV1 (Liljestro$ m & Garoff, 1991) . The NS1 gene was produced as a PCR product from pUC119-T7-NS2 plasmid (E. A. Gould, unpublished results). The PCR reaction was carried out with Pfu DNA polymerase, and the sense and antisense primers were 5h CGGGATCCGCACCATGAGGAACCCCACAATG-TCCATG 3h and 5h GAAGATCTCGCAACCACCATTGAGCGAAC-AAGC 3h. The primers contained BamHI or BglII restriction sites. The sense primer contained sequences for a Kozak element, GCACC. The isolated PCR product was digested with BamHI and BglII and inserted into the BamHI site in pSFV1. Plasmid pSFV3-LacZ has been described previously (Liljestro$ m & Garoff, 1991) .
Analysis of LIV protein expression from rSFV. Metabolic labelling of rSFV-transfected cells with [$&S]methionine was done essentially as described previously (Liljestro$ m & Garoff, 1991) . Briefly, cells were transfected with in vitro-transcribed RNA and incubated for 7n5 h in complete BHK medium. The growth medium was then replaced with methionine-free MEM for 30 min prior to the addition of fresh medium containing 100 µCi\ml [$&S]methionine. After a 20 min labelling period, the cells were incubated further for various times in medium containing 10 times the normal amount of unlabelled methionine. Supernatants were collected and cells were lysed with a Nonidet P-40 buffer containing 100 mM iodoacetamide.
Protein sample preparation and analysis. Cell lysates and medium samples were analysed by immunoprecipitation followed by SDS-PAGE, as described previously (Liljestro$ m & Garoff, 1991 ; Salminen et al., 1992) . To examine whether the E and M proteins released into the supernatant of transfected cells were in particulate form, aliquots were sedimented through a 10 % (w\v) sucrose cushion in a Beckman JA 18.1 rotor at 17 000 r.p.m. for 2 h at 10 mC. Pellets were resuspended in SDS sample buffer, heated to 94 mC and then sonicated for 30 min. Heating and sonication were repeated twice before SDS-PAGE analysis.
Endoglycosidase H (EndoH) digestion was performed after immunoprecipitation with hyperimmune serum. Samples were resuspended in EndoH buffer (1 % SDS, 50 mM sodium citrate, pH 6n0) and heated to 70 mC for 5 min. The supernatant was divided into two aliquots, 5 U EndoH (Boehringer Mannheim) was added to one of each pair of samples and both reaction mixtures were incubated for 6 h at 37 mC before being analysed by SDS-PAGE.
To examine the formation of dimeric NS1, samples were immunoprecipitated with hyperimmune serum, resuspended in SDS sample buffer and divided in two. Samples were then heated to 94 mC or 37 mC for 5 min before being subjected to SDS-PAGE. Radiolabelled samples were quantified by the Fuji Bio-Image analyser system Bas 2000 after exposure to a Bas-III image plate (Fuji).
Production of rSFV particles. Recombinant RNA produced in vitro was packaged into SFV particles as described previously (Berglund et al., 1993) with the following modifications. Medium containing virus was clarified three times by centrifugation at 4 mC in a Beckman JA10 rotor for 30 min at 10 000 r.p.m. The virus particles were sedimented through a 20 % (w\v) sucrose cushion (Beckman SW 28 rotor ; 25 000 r.p.m. for 1n5 h at 4 mC). The virus pellets were resuspended in TNE buffer (50 mM Tris-HCl, pH 7n4, 100 mM NaCl, 0n1 mM EDTA) and aliquots were frozen on dry ice and stored at k70 mC until use. Before use, virus particles were activated in vitro with CaCl # and chymotrypsin, which renders them infectious by cleavage of the spike protein. To determine the titre of the stocks, BHK-21 cells were infected with serial dilutions of activated virus and monitored for expression of antigen by indirect immunofluorescence (Berglund et al., 1993) .
Inoculation of mice.
Groups of 6-week-old female BALB\c mice were inoculated with 10' rSFV-prME, rSFV-NS1 or rSFV-LacZ particles or PBS. Intraperitoneal inoculations were made in a total volume of 250 µl in PBS. Mice immunized i.n. were first lightly anaesthetized with metofane or halathane, and the inoculum was administered into the nares in a total volume of 50 µl. This immunization protocol was repeated after 2 weeks. Two weeks after the second immunization, serum samples were obtained by cardiac puncture. To obtain lung lavage material, mice were immunized twice as above and 3 weeks after the second immunization the mice were sacrificed. PBS (0n5 ml) was introduced into the lungs through the trachea and recovered after rinsing, typically retrieving 250-350 µl.
In challenge experiments with the LI\31 strain of LIV, 6-week-old female BALB\c mice were infected with 100 LD &! virus measured by the route of inoculation, in 5 µl for i.n. infection and 0n5 ml for i.p. infection. Only about 50 % of unvaccinated mice were killed by i.p. infection with high doses of the LI\I strain, so mice were infected with 100 times the minimum dose that gave detectable lethality. Intranasal infection with LI\I gave 100 % lethality at high doses so the LD &! was used.
Antibody assays. Antibodies were detected by ELISA as follows : BHK-21 cells were transfected with rSFV RNA encoding prME, NS1 or LacZ and plated on 96-well cell culture dishes (10& cells per well) in complete BHK medium. After incubation overnight, the cells were fixed with methanol : acetone (1 : 1). The fixed cells were incubated in blocking buffer (BB ; 1 % w\v BSA in 89 mM boric acid, 90 mM NaCl, pH 8n3) for 3 h at room temperature before the addition of twofold serial dilutions of mouse serum in BB. After incubation of the samples overnight at 4 mC, the plates were washed five times with 0n1 % Tween-20 in 150 mM NaCl. Alkaline phosphatase-conjugated anti-mouse IgG in BB was added and the plates were incubated overnight at 4 mC. After washing as above, substrate (p-nitrophenyl phosphate ; 1 mg\ml) was added and the plates were incubated at room temperature until the A %!& was measured. In order to determine the non-specific background of the assay, duplicate samples were tested against cells expressing the LIV proteins and cells expressing LacZ. Horseradish peroxidase-conjugated anti-IgG1 and antiIgG2a secondary antibodies were used to detect the different IgG antibody isotypes with tetramethylbenzidine dihydrochloride as substrate. The reaction was stopped with 1 M sulphuric acid and the A %&! was measured. Serum samples were considered positive only if the A %&! of the test sample was twice that of the LacZ sample. Lung lavage samples were assayed directly without any serial dilution of the material. Duplicate samples were added to plates coated with fixed cells expressing the LIV proteins or LacZ. Total IgG and IgA were measured by using alkaline phosphatase-conjugated secondary antibodies as above.
T-cell proliferation assay. LIV antigens were produced as described previously (Rothman et al., 1989) with some modifications. Briefly, BHK-21 cells were transfected with pSFV-prME, pSFV-NS1 or pSFV-LacZ RNA by electroporation. After incubation overnight, the cells were washed with PBS and collected with a cell scraper. The cells were resuspended in PBS and disrupted by repeatedly passing them through a 27-gauge syringe needle. Aliquots were stored at k70 mC until further use. Immunofluorescence of duplicate samples with specific MAbs (described above) showed that all cells expressed the relevant antigens.
Groups of four female BALB\c mice were immunized i.p. or i.n. with 10' rSFV-prME or rSFV-NS1 particles and boosted after 2 weeks. Three weeks later, spleens were removed and T cells were isolated from groups of pooled spleens with Dynabeads (mouse Thy 1.2) according to the manufacturer's instructions (Dynal). Stimulator spleen cells were prepared from irradiated spleens (2000 rad) from non-immunized female BALB\c mice.
T cells (2i10&) were cultured with stimulator cells (4i10&) and antigens at different dilutions (1 : 50, 1 : 500, 1 : 5000) in DMEM (containing 4n5 g\l glucose) supplemented with 2 mM glutamine, 100 U\ml penicillin, 100 µg\ml streptomycin, 50 µM 2-mercaptoethanol and 10 % foetal bovine serum in 96-well round-bottomed plates. After 4 days incubation at 37 mC in 10% CO # , the cells were pulsed with 1 µCi Pathology. A total of 20 unvaccinated mice showing clinical signs, comprising groups of five mice infected i.n. or i.p. with the LI\I and LI\31 strains, were processed for pathological examination. Five unvaccinated mice infected i.p. with LI\I and showing no clinical signs were also examined, together with all vaccinated mice surviving LI\I challenge and two mice from each group surviving LI\31 challenge to day 21. The mice were anaesthetized with ether and perfused via the left ventricle with 10 % formol saline for 5 min. Perfused mice were left overnight in fixative at 4 mC before the brains and spinal cords were removed and processed for paraffin embedding. Coronal sections (4 µm) were stained with haematoxylin and eosin.
Results

Expression of LIV antigens
LIV sequences encoding prME and NS1 proteins were cloned into pSFV1 under the control of the SFV subgenomic promoter and therefore expressed from a subgenomic RNA molecule after replication of the SFV vector (Fig. 1 a, b) . SFVprME includes the signal sequence from the C terminus of the C protein driving the insertion of prME into the ER membrane, where the individual proteins prM and E are generated by signal peptidase cleavage. SFV-prME RNA transcribed in vitro was transfected into BHK-21 cells and the proteins expressed were examined in pulse-chase experiments. The E protein was translocated into the ER, where it was glycosylated and then secreted from the cell in particulate, EndoH-resistant form (Fig.  2) . Many studies have shown that the prM precursor protein becomes glycosylated and associates with E upon translocation into the ER (Allison et al., 1995 a, b ; Chambers et al., 1990 ; Heinz et al., 1994 ; Schalich et al., 1996) . Precipitation of LIV proteins from lysates revealed the presence of a protein species with an apparent molecular mass corresponding to that predicted for prM (Fig. 2 a, c) . A smaller protein co-sedimenting from the medium with E corresponded in size to the M protein (Fig. 2 b) , suggesting that the precursor was correctly processed in this system. SFV-NS1 encodes the signal sequence from the C terminus of E, which drives its translocation into the ER. Since NS1 lacks a stop-transfer anchor sequence, it is translocated completely into the ER lumen. Pulse-chase experiments performed on SFV-NS1-transfected cells showed that the NS1 protein was translocated into the ER, where it formed glycosylated dimers (Fig. 3 a, c) . NS1 protein was subsequently transported out of the cell as a partially EndoH-resistant, glycosylated, heat-labile dimer (Fig. 3 b, d ) and after a 16 h chase, 83 % of NS1 had been released.
Immune responses in mice after immunization with rSFV particles
The ability of rSFV particles to induce an immune response to LIV proteins was first tested in BALB\c mice by two i.p. inoculations, 2 weeks apart. Two weeks after the boost, serum samples were taken and analysed for the presence of anti-LIV IgG antibodies by ELISA (Fig. 4 a) . Particles encoding prME or NS1 induced high levels of antibodies to the proteins and antibody levels were very similar even when prME and NS1 were used in combination. Mice inoculated with PBS or rSFVLacZ particles showed no detectable anti-prME or anti-NS1 antibodies (data not shown). IgG levels in serum samples taken from PBS-inoculated mice that had survived i.p. challenge with LI\I were found to be similar to those from mice immunized with rSFV-prME or rSFV-NS1 before challenge with LIV (Fig. 4 a) .
In a separate experiment, mice were immunized i.p. or i.n. with rSFV-prME, rSFV-NS1 or rSFV-LacZ particles. Two weeks after the second immunization, serum and lung lavage samples were collected. Both routes of immunization induced similar levels of serum IgG against prME or NS1 antigens (Fig.  4 b) . As an indirect measure of T helper type 1 (Th1) and T helper type 2 (Th2) immune responses, serum levels of IgG1 and IgG2a were titrated by ELISA (Fig. 4 d) . Both routes of immunization induced predominantly IgG2a antibodies, indicating a Th1 response. IgG and IgA antibodies present in lung lavage samples were also analysed (Fig. 4 c) . Both i.n. and i.p. immunization induced similar levels of IgG specific for prME or NS1, but only the i.n. route showed detectable levels of secretory IgA.
To determine whether immunization with rSFV particles expressing LIV antigens could induce T-cell proliferation, mice were immunized twice with rSFV-prME or rSFV-NS1 particles. After 3 weeks, spleens were removed and T cells were tested for the ability to proliferate after incubation with LIV antigens. The results given in Table 1 show that T-cell proliferative responses were induced by both i.p. and i.n. immunization with rSFV-prME and rSFV-NS1.
Outcome of LIV challenge
To determine whether immunization with rSFV particles encoding LIV genes could protect mice from challenge with LIV, mice were vaccinated twice with rSFV-prME, rSFV-NS1, rSFV-LacZ or PBS and challenged with either the prototype LI\31 strain or a less-virulent, antibody-escape variant, LI\I (Table 2) . Mice immunized i.p. with rSFV-prME were protected from i.p. challenge with either strain of LIV. Intraperitoneal or i.n. vaccination with prME also induced lower but significant protection against i.n. challenge with the LI\31 strain of LIV. In contrast, i.p. or i.n. vaccination of mice with rSFV-prME did not induce significant protection against i.n. challenge with the LI\I strain.
Intraperitoneal immunization with rSFV-NS1 significantly protected against i.p. or i.n. challenge with either strain of LIV, whereas i.n. vaccination failed to provide any protection against i.n. challenge. A mixture of rSFV-NS1 and rSFV-prME induced significant protection against either LI\31 or LI\I challenge.
Clinical findings
In unprotected mice, clinical signs after infection were rapidly progressive and included depression, ruffled fur, a hunched-up appearance, dehydration and coma. All clinically affected mice died or were euthanized within 24 h of the onset of detectable illness. For both strains of LIV, severe degenerative and inflammatory lesions in the central nervous system were confined to mice that showed clinical signs. None of the surviving animals showed clinical signs of disease following either i.p. or i.n. challenge, and central nervous system lesions were confined to mild lymphocytic leptomeningeal infiltrates in a minority of LI\31-infected mice that survived challenge to day 21. Lesions in unprotected i.n.- infected mice were generally more severe than in i.p.-infected mice, with greater involvement of forebrain areas including olfactory bulbs.
Discussion
We found that the envelope glycoproteins prM and E expressed by rSFV in transfected cells are correctly modified, processed and transported out of the cell. This material appeared to be similar to the subviral particles that are a normal by-product of flavivirus infection and which have also been found when other types of recombinant vectors have been used to express the same antigens Rice, 1996 ; Schalich et al., 1996) . The NS1 protein has three putative glycosylation sites (Mandl et al., 1989) and glycosylation has been shown to affect secretion of NS1 (Mason, 1989) , virus replication and mouse neurovirulence (Mackenzie et al., 1996 ; Muylaert et al., 1996 Muylaert et al., , 1997 . Indeed, we found that NS1, when expressed from rSFV, was glycosylated and formed heat-labile dimers that were secreted efficiently from transfected cells.
Strong humoral responses and T-cell proliferation were induced after both i.p. and i.n. vaccination. Although IgA was only detected after i.n. immunization, serum levels of E-and NS1-specific IgG and antibody isotype were equivalent for both routes of vaccination and for both antigens. Neutralizing antibodies raised against the envelope proteins probably play a central role in protection from flavivirus disease (Kreil et al., 1998) . Indeed, vaccination with rSFV-prME completely protected mice from i.p. challenge with LI\31, the prototype virus. In contrast, vaccination with rSFV-prME protected only 50 % of the mice against i.n. challenge with LI\31 and did not protect at all against i.n. challenge with LI\I. This, at least in part, could be due to the severity of the i.n. route of challenge. Using the mean time to death and pathological findings as determinants of pathogenicity, we found a higher level of pathogenicity following i.n. as opposed to i.p. infection with LIV. Furthermore, the LI\I virus lacks a critical neutralizing antibody epitope at position 308 in E protein. Although LI\I is somewhat attenuated, escape from neutralization would allow efficient and lethal infection. The presence of IgA did not appear to have any beneficial effect during the i.n. challenge (compare i.n. and i.p. vaccination).
Immunization of mice with rSFV-NS1 by the i.p. route induced significant protection against i.p. or i.n. challenge with either strain of LIV. As with prME, i.n. challenge was more severe and resulted in a higher proportion of deaths as compared with i.p. challenge. Intranasal vaccination failed altogether to induce protection, although there were no apparent differences in serum antibody levels, isotype profile or T-cell proliferation following immunization. While antibodies against NS1 cannot neutralize the virus, passive immunization with anti-NS1 antibodies has been found to result in protection against flavivirus infection (Gould et al., 1986) . NS1 antibodies present on the surface of infected cells could either induce complement-mediated cytolysis (Gould et al., 1986 ; Lai et al., 1991 ; Schlesinger et al., 1990) or antibodydependent cell-mediated cytotoxicity (Schlesinger et al., 1993) . In addition, the induction of major histocompatibility complex class I-specific cytotoxic T lymphocytes or even CD4 + cytotoxic T cells may play a role in NS1-mediated immunity (Green et al., 1993 (Green et al., , 1997 Schlesinger et al., 1993) . Indeed, we have shown that i.n. immunization with rSFV encoding influenza virus nucleoprotein induces CD8 + cytotoxic T lymphocytes less efficiently than does i.p. immunization (Berglund et al., 1999) . The lack of protective immunity revealed by i.n. challenge may thus reflect the mode of immune surveillance, where serum antibodies or T cells are not able to mediate killing of all infected cells before the virus has replicated, produced new progeny virus and entered the brain.
Recombinant alphavirus particles expressing flavivirus antigens have been used for vaccination in two earlier studies. The first of these (Pugachev et al., 1995 b) used recombinant Sindbis virus particles with double subgenomes. These particles carry genes encoding Sindbis virus structural proteins as well as the genes encoding the foreign antigens. When such recombinant particles encoding M and E proteins were used for vaccination, 65 % of mice challenged with Japanese encephalitis virus were protected. However, replication and translation of the subgenomic RNA encoding the Sindbis virus structural proteins in transfected cells will allow the production and spread of progeny virus particles in the vaccinated animal. A more recent study (Colombage et al., 1998) used suicidal rSFV particles encoding Murray Valley encephalitis virus prM and E proteins. However, the protective effect of vaccination could * Mice were monitored daily for 21 days following challenge. The probability compared with PBS or LacZ controls, as calculated using the Fisher exact test, is shown in parentheses. † i.n. inoculation of rSFV particles was administered to anaesthetized mice in a total volume of 50 µl. ‡ i.n. challenge with LIV was in a total volume of 5 µl to unanaesthetized mice.
not be clearly established because of the weak challenge model used. In this study, we have demonstrated that transient antigen expression following vaccination of mice with suicidal rSFV particles can elicit complete protection against severe flavivirus challenge.
In conclusion, both humoral and cellular immune responses against structural and nonstructural proteins of the virus seem to be important and an optimal flavivirus vaccine might require a mixture of structural and nonstructural antigens. This would also reduce the spread of possible escape variants. Experiments are in progress in the natural host, sheep, to evaluate the efficiency of SFV-based LI vaccines expressing these antigens.
